Last updated: September 1, 2026
Daridorexant hydrochloride, marketed as Quviviq by Idorsia Pharmaceuticals, is a dual orexin receptor antagonist for insomnia. Its commercial trajectory depends on three factors: expansion of U.S. payer coverage, conversion from older sedative-hypnotics, and Idorsia's ability to fund commercialization after regaining direct control of key markets.
Quviviq generated approximately CHF 55 million in product sales in 2023, up sharply from its first full commercial year. The product has a differentiated clinical profile, but faces established branded orexin competitors, low-cost generic hypnotics, controlled-substance prescribing restrictions, and a relatively narrow insomnia market.
What is daridorexant hydrochloride and how does it work?
Daridorexant hydrochloride is an oral dual orexin receptor antagonist that blocks orexin-1 and orexin-2 receptors. The mechanism reduces wake signaling without directly activating gamma-aminobutyric acid receptors, as benzodiazepines and several older hypnotics do.
The U.S. Food and Drug Administration approved Quviviq on Jan. 7, 2022, for adults with insomnia characterized by difficulties with sleep onset or sleep maintenance.[1] The approved strengths are 25 mg and 50 mg, taken once nightly within 30 minutes before going to bed.
The FDA classified daridorexant as a Schedule IV controlled substance. That status affects prescribing, pharmacy distribution, refill procedures and patient adoption.[2]
Key product attributes
| Attribute |
Daridorexant hydrochloride |
| Brand |
Quviviq |
| Developer |
Idorsia Pharmaceuticals |
| U.S. commercial rights |
Idorsia |
| Drug class |
Dual orexin receptor antagonist |
| Approved strengths |
25 mg and 50 mg |
| U.S. approval |
January 2022 |
| U.S. controlled-substance status |
Schedule IV |
| European Union approval |
2022 |
| Primary indication |
Adult insomnia |
| Administration |
Once nightly |
| Main competitors |
Belsomra, Dayvigo, zolpidem, eszopiclone, temazepam and behavioral therapy |
How large is the daridorexant market?
The addressable market is large in epidemiological terms but smaller in commercial terms. Chronic insomnia affects a substantial adult population, yet many patients receive no prescription therapy, use over-the-counter products, or are treated through behavioral interventions.
The prescription segment is fragmented. Generic zolpidem and generic eszopiclone retain broad physician familiarity and have low acquisition costs. Orexin antagonists occupy a newer branded segment with higher prices and a safety narrative that emphasizes sleep architecture, next-day functioning and lower dependence potential relative to some traditional hypnotics.
Idorsia reported approximately CHF 55 million in Quviviq product sales for 2023, compared with approximately CHF 12 million in 2022.[3] The increase reflected broader market availability, additional country launches and rising U.S. prescription volume.
Revenue trajectory
| Period |
Reported Quviviq product sales |
Commercial interpretation |
| 2022 |
Approximately CHF 12 million |
Initial launch year |
| 2023 |
Approximately CHF 55 million |
Rapid geographic and prescription expansion |
| 2024 onward |
Dependent on U.S. access and European reimbursement |
Scale-up phase with rising commercial costs |
The product's growth rate has been high because the starting base was small. Future growth will likely be slower in percentage terms and more dependent on refill persistence, formulary placement and physician adoption.
What is driving Quviviq revenue growth?
U.S. market penetration
The United States is the principal commercial opportunity. The U.S. market combines high diagnosis rates, substantial insomnia prevalence and a large branded prescription market. Idorsia's direct commercial control gives it greater access to product economics than a royalty-only arrangement, but also leaves the company responsible for sales, marketing, market access and medical-affairs costs.
Key U.S. growth levers include:
- Coverage by commercial insurers and Medicare Part D plans.
- Lower patient out-of-pocket costs through copay programs.
- Primary-care prescribing rather than dependence on sleep specialists.
- Switching from zolpidem, eszopiclone and sedating antidepressants.
- Greater physician confidence in next-day safety and sleep-maintenance outcomes.
- Continued use in patients who do not respond adequately to behavioral therapy or existing hypnotics.
The U.S. launch also benefits from a clinically defined target population. Quviviq is not positioned as a general sedative. The label focuses on sleep onset and sleep maintenance, allowing promotion around both difficulty falling asleep and difficulty staying asleep.
European expansion
The European Union authorized daridorexant in 2022 for adults with insomnia symptoms lasting at least three months and with considerable impact on daytime functioning.[4] European uptake is more dependent on national reimbursement decisions than on regulatory approval alone.
Germany is an important reference market because of its size and structured reimbursement system. Other European markets can produce incremental volume, but launch timing and net pricing vary materially by country.
European revenue is likely to have lower gross-to-net leakage in some markets than the United States, but price controls and slower formulary negotiations can delay uptake.
Clinical differentiation
Daridorexant's commercial argument rests on efficacy with limited next-day impairment at the recommended doses. Clinical trials showed improvements in sleep onset, sleep maintenance and patient-reported daytime functioning, with somnolence and headache among commonly reported adverse events.[1]
The differentiation is strongest against traditional hypnotics when physicians prioritize:
- Sleep maintenance.
- Next-day functioning.
- A non-GABAergic mechanism.
- Lower concern about tolerance and dependence than with benzodiazepines.
The differentiation is weaker against suvorexant and lemborexant, which use the same broad orexin pathway and already have physician recognition.
How does daridorexant compare with Belsomra and Dayvigo?
| Product |
Active ingredient |
Company |
Mechanism |
Commercial position |
| Quviviq |
Daridorexant |
Idorsia |
Dual orexin antagonist |
Newer entrant with focus on next-day functioning |
| Belsomra |
Suvorexant |
Merck |
Dual orexin antagonist |
First major orexin antagonist; established U.S. brand |
| Dayvigo |
Lemborexant |
Eisai |
Dual orexin antagonist |
Competing branded product with payer and physician presence |
| Ambien and generics |
Zolpidem |
Multiple generic manufacturers |
GABA-A modulation |
Low-cost, high-recognition incumbent |
| Lunesta and generics |
Eszopiclone |
Multiple generic manufacturers |
GABA-A modulation |
Low-cost generic alternative |
Quviviq's main strategic challenge is that its closest mechanistic competitors have already established the orexin category. Its broader commercial challenge is that generic hypnotics are substantially cheaper and deeply embedded in prescribing practice.
The product can gain share without displacing all other orexin drugs. Category expansion is possible if physicians move patients away from older sedative-hypnotics, especially where next-day impairment or dependence is a concern.
What is the Orange Book status of Quviviq?
Quviviq is an FDA-approved small-molecule drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[5] The relevant U.S. patent estate includes composition-of-matter and related protection for daridorexant and its pharmaceutical use.
The core daridorexant patent family includes U.S. Patent No. 9,650,248. The core term extends into the early 2030s based on the underlying priority timeline, subject to patent-term adjustment, patent-term extension and any applicable terminal disclaimers.[6]
Later patents may cover specific solid forms, formulations, dosing regimens or therapeutic uses. Those patents can create additional litigation and launch barriers even when the core compound patent is approaching expiration.
Patent protection relevant to generic entry
| Protection category |
Commercial relevance |
| Active pharmaceutical ingredient |
Strongest barrier to early generic substitution |
| Solid form or salt |
Can limit alternative manufacturing routes |
| Pharmaceutical formulation |
May protect tablets or stability characteristics |
| Dosing regimen |
Can support method-of-use litigation |
| Insomnia treatment method |
May be listed or asserted depending on claim scope |
| Manufacturing process |
Can increase development cost without always blocking a non-infringing route |
A generic applicant seeking approval before relevant patents expire could file an Abbreviated New Drug Application with a Paragraph IV certification. That filing would provide notice of a patent challenge and could trigger patent litigation under the Hatch-Waxman framework.[7]
When does daridorexant lose exclusivity?
The practical U.S. generic-entry date depends on three separate items:
- FDA regulatory exclusivity.
- Expiration of listed patents.
- Any litigation-triggered 30-month stay or court-ordered injunction.
Daridorexant's five-year new chemical entity exclusivity would run from the 2022 FDA approval, barring certain ANDA submissions until 2027.[1] That regulatory period is distinct from patent protection. Patent expiry is expected to remain the more important constraint for full generic entry.
The first realistic generic launch window is therefore likely to be determined by the earliest enforceable patent expiration, not by the end of FDA exclusivity alone. A successful Paragraph IV challenge could accelerate entry. A settlement could delay commercial launch while permitting an agreed entry date.
Generic launch scenarios
| Scenario |
Likely commercial effect |
| No Paragraph IV challenge before core patent expiry |
Branded revenue remains protected until patent expiry |
| Early Paragraph IV filing and settlement |
Potential authorized or licensed generic entry before full expiry |
| Successful patent challenge |
Rapid price erosion and pharmacy substitution |
| Invalidity or non-infringement loss for generic |
Quviviq protection remains intact |
| Narrow formulation patent survives |
Some generic products may enter while branded differentiation persists |
The principal risk is not biosimilar competition. Daridorexant is a chemically synthesized small molecule, so the relevant threat is conventional generic substitution through the ANDA pathway.
Which companies are challenging Quviviq?
Publicly disclosed commercial competition is more significant than publicly established Paragraph IV litigation. Belsomra, Dayvigo and generic hypnotics compete directly for prescriptions, but those products do not constitute patent challenges to Quviviq.
Any Paragraph IV challenge would likely come from a generic manufacturer with experience in CNS products, including large U.S. generic companies and specialized ANDA filers. The competitive threat would become material when an ANDA filer publicly identifies Quviviq patents in a notice letter or litigation docket.
At present, the principal business risk is payer and market competition rather than a confirmed biosimilar or generic launch.
What licensing deals affect daridorexant?
Idorsia initially entered a collaboration with Janssen Pharmaceuticals for the development and commercialization of daridorexant in the United States and Canada. Janssen later exited the collaboration, returning commercial control of Quviviq in those markets to Idorsia.[8]
That change has two opposing effects:
- Idorsia retains more long-term product economics and strategic control.
- Idorsia assumes the cost and execution risk of U.S. commercialization.
The termination also increased the importance of Idorsia's balance sheet. Quviviq must generate enough gross profit to support a broader commercial organization and the company's other pipeline programs.
How strong is the daridorexant patent estate?
The patent estate is commercially meaningful but not unusually broad compared with products protected by multiple formulation, device and combination patents.
Strengths
- Core chemical protection extends beyond the initial FDA exclusivity period.
- The drug has a defined composition and pharmaceutical-use patent position.
- Controlled-substance and prescription requirements can slow substitution even after legal entry.
- Physician and patient familiarity can support residual branded demand.
Weaknesses
- The molecule is a small-molecule oral tablet, making ANDA development technically feasible.
- The insomnia indication has extensive prior art.
- Orexin-antagonist clinical differentiation is shared with Belsomra and Dayvigo.
- Formulation and method-of-use patents may be easier to design around than a strong composition patent.
- Generic entry would likely produce rapid net-price compression.
The strongest protection is the core compound position. Secondary patents may extend litigation complexity but should not automatically be treated as equivalent to composition-of-matter protection.
What FDA regulatory issues affect Quviviq sales?
The FDA label contains several commercial constraints. Quviviq can cause next-day impairment, especially at higher doses or when combined with other central nervous system depressants. It is contraindicated in narcolepsy and carries warnings regarding abnormal thinking, complex sleep behaviors, worsening depression and respiratory effects in vulnerable patients.[1]
These warnings limit broad promotion but also create a clinically defined prescribing framework. Because Quviviq is Schedule IV, Idorsia must manage controlled-substance distribution, abuse monitoring and prescriber education.
The regulatory profile is commercially more favorable than that of some older hypnotics in areas such as mechanism and dependence perception, but it does not eliminate sedative-related safety concerns.
What is the revenue exposure and investment outlook?
Quviviq is strategically important to Idorsia because the company has a limited number of marketed products. The product's sales growth can materially affect operating cash flow, but commercial investment may delay profitability.
The financial trajectory has three phases:
Launch phase: 2022
Revenue was limited by the U.S. launch ramp, controlled-substance logistics and early payer access. Idorsia established the product in the U.S. and began European commercialization.
Expansion phase: 2023 to 2025
Sales growth depended on formulary additions, increased prescriber awareness and direct commercialization after the Janssen transition. The increase to roughly CHF 55 million in 2023 demonstrated market uptake but remained below the scale required to transform Idorsia's overall financial profile.[3]
Maturity phase: later decade
The product's value will depend on whether it reaches a broad primary-care audience before patent-risk discussions intensify. Revenue could grow materially if Quviviq becomes a preferred branded option for sleep-maintenance insomnia. Growth would be weaker if payers place it behind generic zolpidem, Belsomra and Dayvigo.
The main valuation variables are prescription growth, net price, payer coverage, commercial spending, persistence and the timing of generic entry.
Key Takeaways
- Daridorexant hydrochloride is Idorsia's principal marketed growth product under the Quviviq brand.
- U.S. FDA approval occurred in January 2022; the product is a Schedule IV controlled substance.
- Product sales increased from approximately CHF 12 million in 2022 to approximately CHF 55 million in 2023.
- The United States is the primary revenue opportunity and the main execution risk.
- Belsomra, Dayvigo and generic zolpidem are the principal commercial competitors.
- Conventional generic, not biosimilar, competition is the relevant post-exclusivity risk.
- U.S. new chemical entity exclusivity runs into 2027, while patent protection for the core compound extends into the early 2030s based on the principal patent family.
- Secondary formulation, solid-form and method-of-use patents may affect the timing and scope of generic entry.
- Idorsia's return to direct commercialization increases potential product economics but also increases operating and financing pressure.
- Quviviq's long-term value depends on achieving broad payer coverage before generic-entry litigation becomes the dominant market issue.
FAQs
Is daridorexant hydrochloride the same as Quviviq?
Yes. Quviviq is the branded product containing daridorexant hydrochloride.
Does daridorexant have biosimilar risk?
No. Daridorexant is a chemically synthesized small molecule. The relevant regulatory pathway for competitors is an ANDA for a generic drug, not a biosimilar application.
Which insomnia drug competes most directly with Quviviq?
Belsomra and Dayvigo are the closest pharmacologic competitors because all three are dual orexin receptor antagonists. Generic zolpidem is the largest practical commercial competitor because of its low price and prescribing familiarity.
Can a generic version of Quviviq launch before 2030?
A generic could potentially launch before the end of the core patent term through a successful Paragraph IV challenge, a settlement, a license or an authorized-generic arrangement. Without one of those outcomes, patent expiry is the principal constraint.
What is the main financial risk for Idorsia?
The main risk is that Quviviq prescription growth will not generate sufficient gross profit to cover direct commercialization costs, research spending and financing obligations before generic competition reduces pricing power.
References
-
U.S. Food and Drug Administration. (2022). Quviviq (daridorexant) prescribing information. FDA.
-
U.S. Drug Enforcement Administration. (2022). Schedules of controlled substances: Placement of daridorexant into Schedule IV. Federal Register.
-
Idorsia Pharmaceuticals Ltd. (2024). Annual report 2023. Allschwil, Switzerland.
-
European Medicines Agency. (2022). Quviviq: EPAR product information. EMA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,650,248: Orexin receptor antagonists. USPTO.
-
U.S. Food and Drug Administration. (2017). ANDA submissions: Amendments to Abbreviated New Drug Application regulations. FDA.
-
Idorsia Pharmaceuticals Ltd. (2023). Idorsia regains commercial rights for Quviviq in the United States and Canada. Idorsia corporate communications.
